Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +16.10%
#2 Fake World Assets Fake World Assets +11.89%
#3 OriginTrail OriginTrail +8.84%
#4 B3 (Base) B3 (Base) +7.77%
#5 Pons Pons +5.38%
#6 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +4.30%
#7 Audiera Audiera +3.81%
#8 Strategy PP Variable xStock Strategy PP Variable xStock +3.03%
#9 Geodnet Geodnet +2.92%
#10 Ontology Gas Ontology Gas +2.71%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
Classifica tra le azioni #20909
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
Prezzo delle azioni
$1.54
Ultima sincronizzazione: 2024-04-08
Capitalizzazione di mercato
$119.21M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia NGM Biopharmaceuticals, Inc. (NGM)

Categoria

Healthcare
Numero di azioni in circolazione per NGM Biopharmaceuticals, Inc. (NGM)
Numero di azioni in circolazione al August 2026: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di NGM Biopharmaceuticals, Inc., il numero attuale di azioni in circolazione è 0. Alla fine del August 2026, la società aveva 0 azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di NGM Biopharmaceuticals, Inc. (NGM) dal 2026 al 2026
Azioni in circolazione alla fine di ogni anno
Anno Azioni in circolazione Cambia
Non abbastanza dati per le date fornite.
Azioni in circolazione per aziende simili o concorrenti
Azienda Azioni in circolazione Differenza Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH